Outpatient approaches to the treatment of novel coronavirus infection in pregnant and lactating women

The problem of treating the new coronavirus infection COVID-19 in pregnant and lactating women is an urgent problem of world health. According to foreign authors (Mantlo E., Bukreyeva N., Maruyama J., Paessler S., Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020 Jul; 179: 104811) recombinant interferon α is active against the novel coronavirus in vitro in the cell culture model Vero and SARS-CoV-2 (COVID-19). SARS-CoV-2 (COVID-19) is sensitive to recombinant interferon α-2b, but high serum concentrations (more than 300 IU / ml) are required to achieve a therapeutic effect, which are achieved with systemic administration of more than 3,000,000 IU of recombinant interferon α -2b. The article analyzes the clinical symptoms and the effectiveness of therapy for the new coronavirus infection COVID-19 in pregnant and lactating women in outpatient practice with high doses of interferon α-2b (by the decision of the council of doctors). The authors found that complex therapy with high doses of interferon α-2b infection COVID-19 in pregnant women flows relatively favorably and ends with recovery. In lactating women who do not work because of parental leave, the new coronavirus infection had mild clinical symptoms and was accompanied by the development of pneumonia (MSCT I – II) with uncommon lung involvement. As a basic therapy, as well as pregnant women, they were prescribed high doses of recombinant interferon α-2b and β-lactam antibiotic to prevent aggravation of the condition. This therapy made it possible to avoid complications and stop the symptoms of damage to the bronchial tree. 

1. National website CORONAVIRUS (COVID-19) https://coronavirusmonitor.ru/coronavirus-v-omskoj-oblasti/

2. Breslin N., Baptiste C., Gyamfi-Bannerman C., et al. COVID-19 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals // Am J Obstet Gynecol MFM. 2020.

3. Liu D. et al. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis // AJR Am J Roentgenol. 2020: 1-6. DOI: 10.2214/ AJR.20.23072.

4. Nan Yu, Wei Li, Qingling Kang et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COID-19 in Wuhan, China: a retrospective, single-centre, descriptive study // Lancet. 2020, vol. 20. preprint www.thelancet.com/infection.

5. Zimmermann P., Curtis N. COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features // Pediatr Infect Dis J. 2020; 39: 469–477.

6. Wu Y., Liu C., Dong L. et al. Coronavirus disease 2019 among pregnant Chinese women: Case series data on the safety of vaginal birth and breastfeeding // BJOG. 2020 May 5. DOI: 10.1111/1471-0528.16276. [Epub ahead of print].

7. Schwartz D. A. An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes // Arch Pathol Lab Med. 2020; 10.5858, arpa.2020-0901-SA. DOI: 10.5858/arpa.2020-0901-SA, [published online ahead of print, 2020 Mar 17].

8. Westgren M., Pettersson K., Hagberg H., Acharya G. Severe maternal morbidity and mortality associated with COVID-19: The risk should not be down-played // Acta Obstet Gynecol Scand. 2020 May 9. DOI: 10.1111/aogs.13900. [Epub ahead of print].

9. Hantoushzadeh S., Shamshirsaz A. A., Aleyasin A. et al. Maternal Death Due to COVID-19 Disease // Am J Obstet Gynecol. 2020 Apr 28. Pii: S0002- 9378(20)30516-0. DOI: 10.1016/j.ajog.2020.04.030. [Epub ahead of print].

10. Lamouroux A., Attie-Bitach T., Martinovic J., Leruez-Ville M., Ville Y. Evidence for and against vertical transmission for SARS-CoV-2 (COVID-19) // Am J Obstet Gynecol. 2020 May 3. Pii: S0002-9378(20)30524-X. DOI: 10.1016/j.ajog.2020.04.039. [Epub ahead of print].

11. Organization of medical care for pregnant women, women in labor, maternity hospitals and newborns with a new covid-19 coronavirus infection. Guidelines, Ministry of health of the Russian Federation, version from may 2020. 56 p.

12. Temporary guidelines for the prevention, diagnosis and treatment of a new coronavirus infection 2019-nCoV. Ministry of health of Russia. Version 6 from 24.04.2020. 142 p.

13. Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). https://www.cdc.gov/coronavirus/ 2019-ncov/hcp/clinicalguidance-managementpatients.html. Accessed March 8, 2020.

14. Alessandro Favilli A., Mattei Gentili M., Francesca Raspa, Giardine I. et al. Effectiveness and Safety of Available Treatments for COVID-19 During Pregnancy: a Critical Review // The Journal of Maternal-Fetal & Neonatal Medicine. 2020, ahead-of-print, 1–14. https://doi.org/10.1080/14767058.2020.1774875.

15. Mantlo E., Bukreyeva N., Maruyama J., et al. Antiviral activities of type I interferons to SARS-CoV-2 infection // Antiviral Res. 2020; 179: 104811.

16. Yazdani B. P., Matok I., Garcia B. F. et al. A systematic review of the fetal safety of interferon alpha // Reprod Toxicol. 2012; 33 (3): 265–268.

17. Maleeva L. I., Sergeev V. V., Pechenkina S. I., Kuznetsov V. P. Influence interferon drug to increase the sensitivity of bacteria to antibiotics // Antibiotics and chemotherapy. 1988. № 11. P. 820–823.

18. Simbirtsev A. S. Clinical use of cytokine preparations // Immunology. 2004. Vol. 25. No. 4. P. 247-251.

19. Malinovskaya V. V., Dilanyan N. V., Arinenko R. Yu., Meshkov E. N. Viferon. Complex antiviral and immunomodulatory drug for children and adults. Guide for doctors. Moscow: INKO-TNK, 2005.